Skip to contentV
Vaccinex, Inc.
V
VCNXVaccinex, Inc. Q3 2022 · 10-Q
Revenue$50.00K$50.00K±0.0% vs Q3 2021 Net Income-$4.76M-$4.76MN/M vs Q3 2021 EPS Diluted-$1.67-$1.67N/M vs Q3 2021 Operating Income-$4,792,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaccinex, Inc. · CIK 1205922 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$4,195,000N/M Margins · derivedOperating margin-9584.0%+542.0 pt vs Q3 2021
Net margin-9518.0%+894.0 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end